Table 2.

Baseline disease characteristics for the APHINITY study

Chemotherapy, trastuzumab and pertuzumab N = 2,400, n (%)Chemotherapy, trastuzumab and placebo N = 2,404, n (%)
Nodal status
 Negative897 (37.4)902 (37.5)
 1–3 Positive907 (37.8)900 (37.4)
 ≥4 positive596 (24.8)602 (25.0)
Pathologic tumor size and nodal status
 <1 cm and node negative58 (2.4)60 (2.5)
 ≥1–<2 cm and node negative417 (17.4)391 (16.3)
 ≥2 cm and node negative421 (17.5)450 (18.7)
 <1 cm and node positive86 (3.6)68 (2.8)
 ≥1–<2 cm and node positive416 (17.3)425 (17.7)
 ≥2 cm and node positive999 (41.6)1,007 (41.9)
Hormone receptor status
 ER and/or PR positive1,536 (64.0)1,546 (64.3)
 ER and PR negative864 (36.0)858 (35.7)
HER2 status (central)
 06 (0.3)2 (<0.1)
 1+16 (0.7)9 (0.4)
 2+193 (8.0)200 (8.3)
 3+2,184 (91.0)2,190 (91.2)
Primary surgery
 Breast conservation1,118 (46.7)1,076 (44.8)
 Mastectomy1,280 (53.3)1,327 (55.2)
 Anthracycline-based chemotherapyregimen1,865 (77.7)1,877 (78.1)
  • Abbreviations: ER, estrogen receptor; PR, progesterone receptor.